Literature DB >> 26942729

[Nephroblastomas: Almost exclusively in clinical trials!].

P K Bode1, H Moch2.   

Abstract

Nephroblastomas are the most commonly occurring renal neoplasms in childhood and are treated almost exclusively in clinical trials. An important factor for further therapeutic management is the pathological evaluation of the nephrectomy specimen. Tumor stage and risk group classification are the most crucial parameters. An independent assessment of the tumor by a reference pathology center is an essential standard procedure. Although many molecular genetic discoveries have been made in nephroblastomas over recent years, molecular parameters do not (yet) play a role in treatment stratification.

Entities:  

Keywords:  Cancer; Childhood; International Society of Paediatric Oncology; Nephroblastoma; Wilms tumor

Mesh:

Year:  2016        PMID: 26942729     DOI: 10.1007/s00292-016-0148-x

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  17 in total

Review 1.  Wilms' tumour: connecting tumorigenesis and organ development in the kidney.

Authors:  Miguel N Rivera; Daniel A Haber
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

Review 2.  Wilms tumor and the WT1 gene.

Authors:  S B Lee; D A Haber
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

Review 3.  Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour.

Authors:  R H Scott; C A Stiller; L Walker; N Rahman
Journal:  J Med Genet       Date:  2006-05-11       Impact factor: 6.318

4.  Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.

Authors:  Jeffrey S Dome; Cecilia A Cotton; Elizabeth J Perlman; Norman E Breslow; John A Kalapurakal; Michael L Ritchey; Paul E Grundy; Marcio Malogolowkin; J Bruce Beckwith; Robert C Shamberger; Gerald M Haase; Max J Coppes; Peter Coccia; Morris Kletzel; Robert M Weetman; Milton Donaldson; Roger M Macklis; Daniel M Green
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

Review 5.  Wilms tumor.

Authors:  Andrew M Davidoff
Journal:  Adv Pediatr       Date:  2012

6.  Complete necrosis induced by preoperative chemotherapy in Wilms tumor as an indicator of low risk: report of the international society of paediatric oncology (SIOP) nephroblastoma trial and study 9.

Authors:  L Boccon-Gibod; A Rey; B Sandstedt; J Delemarre; D Harms; G Vujanic; J De Kraker; A Weirich; M F Tournade
Journal:  Med Pediatr Oncol       Date:  2000-03

Review 7.  Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.

Authors:  Vicki Huff
Journal:  Nat Rev Cancer       Date:  2011-01-20       Impact factor: 60.716

8.  Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors.

Authors:  Jenny Wegert; Naveed Ishaque; Romina Vardapour; Christina Geörg; Zuguang Gu; Matthias Bieg; Barbara Ziegler; Sabrina Bausenwein; Nasenien Nourkami; Nicole Ludwig; Andreas Keller; Clemens Grimm; Susanne Kneitz; Richard D Williams; Tas Chagtai; Kathy Pritchard-Jones; Peter van Sluis; Richard Volckmann; Jan Koster; Rogier Versteeg; Tomas Acha; Maureen J O'Sullivan; Peter K Bode; Felix Niggli; Godelieve A Tytgat; Harm van Tinteren; Marry M van den Heuvel-Eibrink; Eckart Meese; Christian Vokuhl; Ivo Leuschner; Norbert Graf; Roland Eils; Stefan M Pfister; Marcel Kool; Manfred Gessler
Journal:  Cancer Cell       Date:  2015-02-09       Impact factor: 31.743

Review 9.  Molecular findings in Beckwith-Wiedemann syndrome.

Authors:  Sanaa Choufani; Cheryl Shuman; Rosanna Weksberg
Journal:  Am J Med Genet C Semin Med Genet       Date:  2013-04-16       Impact factor: 3.908

10.  Gain of 1q is a marker of poor prognosis in Wilms' tumors.

Authors:  H Segers; M M van den Heuvel-Eibrink; R D Williams; H van Tinteren; G Vujanic; R Pieters; K Pritchard-Jones; N Bown
Journal:  Genes Chromosomes Cancer       Date:  2013-09-04       Impact factor: 5.006

View more
  1 in total

Review 1.  [Rare childhood kidney tumors].

Authors:  C Vokuhl
Journal:  Pathologe       Date:  2019-11       Impact factor: 1.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.